Rapid-acting insulin compositions
US-2017056478-A1 · Mar 2, 2017 · US
Pharmaceutical combinations comprising insulin and at least an agent selected from meloxicam, bromfenac sodium, acetylsalicylic acid, salicyclic acid and paracetamol
US11510967B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11510967-B2 |
| Application number | US-201816645199-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 30, 2018 |
| Priority date | Sep 8, 2017 |
| Publication date | Nov 29, 2022 |
| Grant date | Nov 29, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutical composition comprising an insulin selected from rapid acting insulin or ultra-rapid acting insulin, wherein the insulin concentration is from about 100 U/mL to about 500 U/mL; about 2.5 mg/mL to about 3.8 mg/mL of m-cresol; and about 0.025 mg/mL to about 3.0 mg/mL of meloxicam, wherein the composition has a pH between about pH 7 to about pH 7.8 at room temperature. 2. The pharmaceutical composition as claimed by claim 1 wherein the insulin concentration is from about 100 U/mL to about 200 U/mL. 3. The pharmaceutical composition as claimed by claim 2 wherein the insulin concentration is about 100 U/mL. 4. The pharmaceutical composition as claimed by claim 1 wherein the m cresol concentration is from about 3.0 mg/mL to about 3.5 mg/mL. 5. The pharmaceutical composition as claimed by claim 4 wherein the m-cresol concentration is about 3.15 mg/mL. 6. An article of manufacture comprising the pharmaceutical composition as claimed by claim 1 . 7. The article of manufacture as claimed by claim 6 wherein the article of manufacture is a multi-use vial. 8. The article of manufacture as claimed by claim 6 the article of manufacture is a multi-use cartridge. 9. The article of manufacture as claimed by claim 6 the article of manufacture is a pump device for continuous subcutaneous insulin infusion therapy. 10. The pharmaceutical composition as claimed by claim 1 wherein the insulin is insulin lispro. 11. The pharmaceutical composition as claimed by claim 1 wherein the insulin is ultrarapid insulin.
Assignees
Inventors
Classifications
Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
Zinc; Compounds thereof · CPC title
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title
- A61K38/28Primary
Insulins · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11510967B2 cover?
- The present invention relates to pharmaceutical insulin compositions comprising insulin, a preservative, and at least one selected from the group consisting of aspirin, acetaminophen, dexamethasone, heparin, meloxicam, bromfenac sodium, salicylic acid; and the use of the compositions to treat diabetes.
- Who is the assignee on this patent?
- Lilly Co Eli
- What technology area does this patent fall under?
- Primary CPC classification A61K38/28. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).